Page 1,482«..1020..1,4811,4821,4831,484..1,4901,500..»

New approach in T-cell therapy to treat cancer – Medical Xpress

Posted: June 8, 2017 at 9:42 am

June 8, 2017 T cells attack a tumor cell and secrete lytic proteins (red/yellow) in order to destroy it. Credit: Helmholtz Zentrum Mnchen

Scientists have armed immune cells with a new surface molecule. This causes the cells to respond particularly aggressively when they encounter a protein that tumors actually use to camouflage themselves from the immune system. Researchers from the Helmholtz Zentrum Mnchen and various partners introduced the method in Cancer Research.

With numerous different entities and millions of people affected, cancer continues to be one of the most prevalent diseases around the world. Scientists are working to find new treatment possibilities, and have been concentrating on the body's own immune system for some time.

"Because cancer emerges from the body's own cells, it is usually difficult for the immune system to distinguish good cells from bad ones," explains Prof. Dr. Elfriede Nner, head of the Tissue Control of Immunocytes Research Group at the Helmholtz Zentrum Mnchen. "But there are ways to support the immune system in recognizing and combating cancer cells."

Focus on T-cell therapy

One approach is the so-called adoptive T-cell therapy, which involves removing immune cells from the body and genetically arming them. The cells are given new structures on the surface that accurately lead them to the cancer cells.

One limitation in this form of therapy is that the binding between the immune cell and the cancer cell is often somewhat weak. "Although this binding can be artificially strengthened, doing so also increases the risk of unwanted binding to healthy structures in the body," explains study leader Nner. She and her team were therefore searching for a different way to improve the defense provided by the immune cells.

Attack instead of sleep mode

In the current work, the researchers present a new surface molecule which comprises two halves. On the outside, it preferentially binds to the PD-L1 molecule, which tumor cells often form in order to thwart the attacking immune cells. On the inside of the T-cells, however, this binding does not activate a sleep mode (which the natural protein would do), and instead activates the T-cell's killer program, making it especially aggressive. Experimental models showed that T-cells armed in this way proliferate more strongly in the tumors and destroyed more tumor cells.

The next step will be to confirm the findings in clinical studies. "If that step succeeds, the approach would enlarge the arsenal of T-cells suitable for adoptive T-cell therapy," Elfriede Nner states. "This could not only make the treatment more effective but would allow it to be used in more patients in the framework of personalized medicine."

Explore further: Platelets suppress T cell immunity against cancer

More information: Ramona Schlenker et al. Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy, Cancer Research (2017). DOI: 10.1158/0008-5472.CAN-16-1922

Blood platelets help disguise cancer from the immune system by suppressing T cells, report scientists at the Medical University of South Carolina (MUSC) in the May 5, 2017 issue of Science Immunology. In extensive preclinical ...

Epstein-Barr virus (EBV) prevents infected cells from being attacked by the immune system. The virus drives production of small molecules, so-called microRNAs, that suppress alarm signals sent out by the infected cell. Scientists ...

Immunotherapy is a new and highly promising form of treatment for cancer. In many patients, however, tumors recur after immunotherapy. In the latest issue of the Journal of Experimental Medicine, the members of a research ...

Researchers of the Cancer Virotherapy Research Group of Bellvitge Biomedicine Research Institute (IDIBELL), led by Dr. Ramon Alemany, have developed an oncolytic virus capable of redirecting the patient's immune system against ...

The Shin Kaneko lab found that reprogramming one type of iNKT cells to iPS cells and then differentiating them back results in reprogrammed iNKT cells (re-iNKT cells) that show properties of another type. The ability to make ...

Adult stem cells from mice converted to antigen-specific T cells -- the immune cells that fight cancer tumor cells -- show promise in cancer immunotherapy and may lead to a simpler, more efficient way to use the body's immune ...

Researchers at ANU are working on a new treatment for an aggressive type of leukemia that outperforms standard chemotherapies.

Scientists have armed immune cells with a new surface molecule. This causes the cells to respond particularly aggressively when they encounter a protein that tumors actually use to camouflage themselves from the immune system. ...

Researchers have found a new way to use immunotherapy, a breakthrough mode of cancer treatment which harnesses the patient's immune system, to treat an aggressive form of breast cancer.

Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic cancer, according to a study at The University of Texas MD Anderson Cancer Center.

Patients who receive the standard surgical treatment for melanoma that has spread to one or more key lymph nodes do not live longer, a major new study shows.

An analysis of breast cancer data revealed that many small breast cancers have an excellent prognosis because they are inherently slow growing, according to Yale Cancer Center experts. Often, these cancers will not grow large ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the original post here:
New approach in T-cell therapy to treat cancer - Medical Xpress

Posted in Cell Therapy | Comments Off on New approach in T-cell therapy to treat cancer – Medical Xpress

Bioquark Hopes to Bring Dead Back to Life Using Stem Cell Therapy – India West

Posted: June 8, 2017 at 9:42 am

A Philadelphia-based company along with an Indian orthopedic surgeon has said it will start a new type of stem cell therapy that claims it can bring people back from the dead.

Bioquark, led by chief executive Ira Pastor, said it will begin conducting trials of the therapy later in the year in an undisclosed country in Latin America, according to a New York Post report.

Pastor and Indian orthopedic surgeon Himanshu Bansal had initially hoped to run tests in India in 2016 but the Indian Council of Medical Research pulled the plug on their plans and asked them to take the trials elsewhere, the Post reported.

Most countries officially declare someone dead when there is irreversible loss of brain function. The Bioquark therapy boasts it can reboot the brain.

The company said it will begin testing on humans, with no plans to experiment on animals.

Scientists plan to examine individuals aged between 15 and 65 who have been declared brain dead from a traumatic brain injury, the report noted, citing a published study.

The three-stage process starts with harvesting stem cells from the patients own blood before injecting them back into their body. Next, the patient is given a dose of peptides injected into their spinal cord. The final step is a 15-day course of laser and median nerve stimulation while monitoring the patient with MRI scans.

Bansal practices in New Delhi.

Continue reading here:
Bioquark Hopes to Bring Dead Back to Life Using Stem Cell Therapy - India West

Posted in Cell Therapy | Comments Off on Bioquark Hopes to Bring Dead Back to Life Using Stem Cell Therapy – India West

Health & Wellness: 4 most effective ways to control gestational … – Daily Herald

Posted: June 8, 2017 at 9:41 am

When I was pregnant with my fifth baby, I went into the doctors office and found out that I was at risk for gestational diabetes.

I had been preparing for the big event everything from new clothes to a brand new baby carrier but didnt really think about what I had been eating.

As part of everyones prenatal care, about 24 to 28 weeks into your pregnancy, your physician will perform a simple blood test to evaluate how your body reacts to insulin. For almost 10 percent of expectant moms, those results indicate gestational diabetes.

Gestational diabetes poses health risks for the baby, such as high birth weight, jaundice and breathing problems. It can also put you at risk for serious health problems, like high blood pressure and preeclampsia a potentially fatal condition that damages your kidneys and other organs. But, even if you have gestational diabetes, you can minimize your risk with a good diet and exercise plan.

If you have been diagnosed, here are four proven ways to control the negative effects of gestational diabetes:

Leading an active lifestyle is important for everyone, particularly pregnant women. The good news is that it doesnt require a lot of time to benefit from exercise. A simple 10-minute walk around the block or a relaxing yoga session can also help maintain a healthy weight and relieve stress while keeping GD in check.

Doesnt it seem like comfort foods always taste better when you are pregnant? A glass of milk and a doughnut or two or five really satisfy. But many of those foods we crave are loaded with carbohydrates, and that can spike our blood sugar levels. Instead, focus on fresh fruits and vegetables, and whole grains. For example, tart cherries are a delicious addition to your diet.

Tart cherries have been proven to reduce pain and inflammation, Pam Nisevich Bede, RD., a sports nutrition expert, said, adding that cherries reduce arthritic and joint pain and improve heart health.

To avoid spikes in blood sugar levels, try spreading smaller meals throughout the day. Doctors recommend eating three meals and two to three snacks per day. Eating smaller meals more frequently can help you keep your blood sugar levels stable.

By shifting your diet to include low-glycemic foods, you can better control symptoms of gestational diabetes.

Whether you are pregnant or want to be in the near future, its never too late to change your diet, said Ricardo Rueda, MD, PhD. Make an effort to include foods that dont cause sharp rises in your blood sugar and those that have slowly digestible carbs. Doing so lowers your risk of gestational diabetes and, for your baby, it lowers the risk of future obesity.

Fortunately, its easy to incorporate low-glycemic foods into your diet. There are a variety of fresh fruits and vegetables, whole grain cereals and bread, lean cuts of meat, and nonfat dairy products from which to choose.

Pregnancy really is an opportunity to give you and your baby the best start toward healthy futures. By maintaining healthy blood sugar levels with regular exercise, a sensible, balanced diet consisting of frequent meals throughout the day, and talking regularly with your doctor about occurring symptoms, women can still have a happy and healthy pregnancy even with gestational diabetes.

Amy Osmond Cook, Ph.D., is the executive director of the Association of Skilled Nursing Providers, Publisher of 39forlife.com, and CEO of Osmond Marketing. Follow her at @doctorosmond.

View original post here:
Health & Wellness: 4 most effective ways to control gestational ... - Daily Herald

Posted in Diabetes | Comments Off on Health & Wellness: 4 most effective ways to control gestational … – Daily Herald

Baptist camp helps kids fight diabetes – The Commercial Appeal

Posted: June 8, 2017 at 9:41 am

Camp Day2Day is a free camp for youth diagnosed with diabetes or prediabetes sponsored by Baptist Memorial Health Care and the American Diabetes Association. Jim Weber/The Commercial Appeal

Day camper Blayn Dennington withCamp Day2Day checks his blood sugar at the Kroc Center Tuesday afternoon during a break in activities. Camp Day 2Day is a free camp for youth diagnosed with diabetes or prediabetes sponsored by Baptist Memorial Health Care and the American Diabetes Association.(Photo: Jim Weber/The Commercial Appeal)Buy Photo

Like any kidat summer camp, Russell Johnson enjoys theusual offerings of swimming, badminton and touch football, but what will stick with the 12-year-oldmost from the event he's attendingthis week is alesson about how toshopat the supermarket.

"Don't get junk," says the Germantown Middle School student.

Russell was among 32 kids registered forCamp Day2Day, an event for youngsters diagnosed with diabetes or prediabetes, along with those considered at-risk for the disease because of family history and other factors. It'sput on free of charge at The Kroc Center Memphis by Baptist Memorial Health Care and the American Diabetes Association.

The camp's attendance isup45percent from the 22 on hand last year, a reflection, perhaps, of the growing awareness of the perils of diabetes and its grip on the Memphis area.

The city lies within a"diabetes belt" -- a region covering 644 counties in 15 states -- identified by the federal Centers for Disease Control and Prevention. It's an area where at least11 percent of the adult population has been diagnosed with diabetes, an incurable disease characterized by an excess of glucose in the blood, which can lead to nerve damage, blindness, kidney disease, heart trouble and death.

In Shelby County, more than 82,000 residents had been diagnosed with diabetes in 2013, the most recent year for which figures are available, and some 250 people die from it annually.

Camp Day2Day, which attracted kids aged6 through 16,this year includesabout eight youngsterswithType 1 diabetes, traditionally called juvenile diabetes, in which the pancreas produces little or no insulin. Onecamper, Russell, hasType 2 diabetes, the most common form, which occurs when the body develops insulin resistance and can't use the hormone properly.

Autoplay

Show Thumbnails

Show Captions

Another 5 have been diagnosed with prediabetes, meaning their blood-sugar levels are elevated, but not enough so to be considered diabetic. Most of the remainder were considered at-risk for the disease.

Because Type 2 often stems from obesity or poor eating habits, the camp teaches kids about the importance of a healthful diet and exercise. They learn about portion sizes, counting carbohydrates and, during a field trip to a grocery story, how to choose the right foods.

Russellcan trace his disease largely to family history. His mother had diabetes and died from complications and other factors at age 44, and several other family members have been afflicted.

Russell said he'll benefit most from lessons about how to read nutrition labels and keep his weight in check. Heplans a career in nursing.

"I want to help other people who have diabetes," he said.

Another camper, 12-year-old Andrew Lopez, said the activities such as swimming and footballwill helpprevent his prediabetes from progressing to diabetes.

"Mostof my day I like to spend sitting down reading, watching TV," he said. "Being in this environment helps me be more active."

The camp is modeled on the National Diabetes Prevention Program, which focuses on diet, exercise and behavioral changes. The program, developed by the CDC and implemented by local hospitals and health-care providers, seems to have had an impact locally. Between 2008 and 2013, the number of new cases diagnosed in the county fell nearly 19 percent, from 7,918 to 6,439, according to CDC figures.

Day campers Seraiah Johnson and Mallory Johnson (right) withCamp Day2Day play something akin to basketball at the Kroc Center Tuesday afternoon. Camp Day 2Day is a free camp for youth diagnosed with diabetes or prediabetes sponsored by Baptist Memorial Health Care and the American Diabetes Association.(Photo: Jim Weber/The Commercial Appeal)

Jennifer Reed, diabetes education program manager for the Baptist Medical Group Outpatient Care Center, and Melissa Wilson, community health strategist with the ADA, said they're confident the camp can help the kids either avoid developing full-blown diabetes, or, if they already have the disease,at least manage it so they don't develop the debilitating complications.

"It's a process," Reed said. "We hope they'll walk away with a better understanding."

Reach Tom Charlier atthomas.charlier@commercialappeal.comor 901-529-2572 andon Twitter at @thomasrcharlier.

Read or Share this story: http://memne.ws/2sCPPFe

Read the original here:
Baptist camp helps kids fight diabetes - The Commercial Appeal

Posted in Diabetes | Comments Off on Baptist camp helps kids fight diabetes – The Commercial Appeal

Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin … – Kaiser Health News

Posted: June 8, 2017 at 9:40 am

By Emily Kopp June 7, 2017

We encourage organizations to republish our content, free of charge. We dont require much.

For those who need to know the legal underpinnings of using our content, we make it available under the Creative Commons CC BY 4.0 license. Heres what we ask:

You must credit us as the original publisher, with a hyperlink to our site: Kaiser Health News. If possible, please include the original author(s) and Kaiser Health News in the byline. If youd like to explain more about who we are, please use: a national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation. You may use our logo when linking to or posting materials on your site: Download high-resolution .PNG file

Please preserve the hyperlinks in the story.

Its important to note, not everything on khn.org is our original content or available for republishing. If a story is labeled All Rights Reserved, KHN cannot grant permission to republish that item.

Have questions? Let us know at KHNHelp@kff.org

Patients notched a rare win over the pharmaceutical industry Monday when the Nevada Legislature revived a bill requiring insulin makers to disclose the profits they make on the life-sustaining drug. In a handful of other states, bills addressing drug prices have stalled.

Many of the 1.25 million Americans who live with Type 1 diabetes cheered the legislative effort in Nevada as an important first step in their fight against skyrocketing costs of a drug on which their lives depend. The cost of insulin medications has steadily risen over the past decade by nearly 300 percent.

Prominent patient advocacy groups, like the American Diabetes Association, have maintained stony silence while diabetes patients championed the bill and lobbied the legislature during this debate a silence that patients and experts say stems from financial ties.

Normally all of the patient advocacy groups rally around causes and piggyback on each other in a productive way thats what advocacy groups are good at but that hasnt been the case here, said Thom Scher, chief operating officer of Beyond Type 1, which does not accept donations from the pharmaceutical industry. Beyond Type 1 has not issued a formal opinion on the Nevada bill.

Many of the dozens of U.S. diabetes advocacy organizations, large and small, garner significant portions of their funding from insulin manufacturers. The Nevada bill also requires such organizations operating in-state to disclose all contributions they receive from the pharmaceutical industry to discourage that sort of conflict.

In 2016, two of the big three insulin producers Eli Lilly and Sanofi contributed at least $4.7 million to such national patient advocacy groups as the American Diabetes Association, Diabetes Patient Advocacy Coalition (DPAC), JDRF International and the Diabetes Hands Foundation, according to company disclosures. The third major insulin manufacturer, Novo Nordisk, does not disclose its charitable contributions.

The advocacy groups have taken no position on the Nevada legislation. Generally speaking, their advocacy focuses on pressuring insurers to pay the price of insulin, not protesting price rises.

Local diabetes groups, hardly free from conflicts with the pharmaceutical industry, have also stayed on the sidelines.

The Nevada Diabetes Association for Children and Adults officially issued a neutral opinion.

The Nevada Diabetes Association supports regulations on medications. The problem with SB 265 is that it is not just regulating medication but the industry, said Executive Director Sarah Gleich.

The nonprofit does not list its fiscal sponsors on its website or most recent 990 tax form.

We disclose what we have received, and the IRS does not require that we publicly publish from whom, Gleich said. No one is giving out their invitation list to the party.

Gleich said the Nevada Diabetes Association receives table sponsorships and supplies for camp programs from the pharmaceutical industry but nothing that would make a dent on the budget. Auditing non-monetary donations in order to meet the bills transparency requirement would be burdensome, Gleich said.

Membership dues accounted for only about $6,000 of the groups $320,000 in revenue last year, according to its latest tax form.

The American Diabetes Association which operates a Nevada chapter accepted at least $3.9 million from Eli Lilly and Sanofi last year.

The American Diabetes Association believes that no individual in need of lifesaving medications such as insulin should ever go without due to prohibitive costs, Michelle Kirkwood, its director of strategic communications and media relations, said in a statement. She would not say whether the nonprofit supports the bill.

Former American Diabetes Association president Larry Hausner wrote an op-ed in the Nevada Appeal opposing the legislation. Caring for people with diabetes involves more than what they pay for insulin or another medication, Hausner wrote. As a lifelong patient advocate, I know Nevadans expect more out of their elected officials. Hausner, now the president of a consulting and public affairs firm, serves on the board of directors of Research!America, a nonprofit promoting increased federal funding for public health research, alongside Sanofis president of global research & development, Elias Zerhouni.

The Diabetes Hands Foundation expressed neutrality on the bill. This state priority in Nevada is a good step towards a larger conversation about the costs of chronic care conditions like diabetes, said the foundations director of advocacy, Mandy Jones. But its hard to know the particular outcome of this particular bill in the U.S. market.

JDRF International would not comment. DPAC deferred questions to the National Diabetes Volunteer Leadership Council.

Against the backdrop of silence from these patient advocacy groups, a community of diabetes patients on Twitter elevated the bills profile around the hashtag #insulin4all, created by T1International, a group in the United Kingdom that does not accept pharmaceutical donations.

People feel frustrated. At the federal level, were not being seen because theres so much going on politically, said Erin Gilmer, aColorado advocate with Type 1 diabetes. It might have to be a state-by-state movement.

Sen. Yvanna Cancela, who sponsored the bill, said she believed requiring diabetes advocacy groups to reveal their sources of funding was key to understanding their positions and bringing prices down. I believe there should be transparency across the health care system, Cancela said.

Gov. Brian Sandoval said Monday night that he intends to sign the bill, according to a Nevada Independent reporter. If the governor takes no action, the transparency rules become law. The bill, SB539, incorporates provisions of an earlier bill approved by the legislature but vetoed by Sandoval. Sponsors stripped a controversial provision that would have required insulin manufacturers to warn patients 90 days before raising prices, which stoked concerns about drug stockpiling, the Associated Press reported Monday.

The Nevada bill is definitely a step in the right direction, said Elizabeth Rowley, founder and director of T1International. Almost anything requiring more transparency is incredibly important right now, especially at a time when almost all diabetes patient advocacy groups take funding from drug and device companies.

Laura Marston, an advocate in Washington, D.C., with Type 1 diabetes, said that there is plenty of grass-roots support for legislation on insulin prices but that advocacy organizations are not listening to the right people.

There should be more focus on the one thing we need to survive. Without insulin, I die a horrendous death in 12 to 24 hours, Marston said. No grass-roots support? Theres desperation.

KHNs coverage of prescription drug development, costs and pricing is supported in part by the Laura and John Arnold Foundation.

Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation.

See more here:
Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin ... - Kaiser Health News

Posted in Diabetes | Comments Off on Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin … – Kaiser Health News

Amarillo group fills gap left by juvenile diabetes foundation’s closure … – Amarillo.com

Posted: June 8, 2017 at 9:40 am

Courtney Warren arrived at the Amarillo offices of the Juvenile Diabetes Research Foundation two years ago with her sister and 3-year-old nephew, Bray Jones, who had been diagnosed with Type 1 diabetes after a test revealed his blood sugar was six times the normal amount.

Warren remembers how her family struggled to understand Brays diagnosis, and she said learning to live with a Type 1 child was exhausting for the family.

Warren said the family leaned on JDRF at the time. So, when the foundation closed its West Texas Plains branch in October to redirect funds for more research, Warren joined with a group of concerned parents of children with Type 1 diabetes and past JDRF executive board members to develop a group to help fill the gap.

Now Warren is vice president of Type One Area Diabetics Support, or TOADS, which launched in Amarillo last week under the 501(c)(3) umbrella of the Family Care Foundation. One of the new organizations primary goals is to make sure families are supported.

You dont sleep at night, Warren said of having a young family member with Type 1 diabetes.

You have to test your kid every two hours to test their blood sugar, and theres a thing called dead in bed where they have really low blood sugar and then they just basically fall into a coma and pass away.

Its horrible and really scary, she said

TOADS five-goal plan is to provide support, education, Continuous Glucose Monitoring device drives, tactical kits for hospital visits and scholarships for diabetes camps and eventually college.

Warren said she met with a family last week whose son was recently diagnosed with Type 1 diabetes.

Just the fact that they were there, they were scared and we met them that alone is worth it, Warren said. They have someone they can lean on and have a group they can go to.

Warren said she also wants to go into schools and educate children about why they shouldnt see shame in a Type 1 diagnosis.

TOADS is planning its first large fundraiser this fall, Warren said, and theyre hoping to raise $100,000 for local support.

We just want to help the Type 1s and their families because its a scary diagnosis, Warren said.

We dont have a cure yet, and JDRF is the leading research (group) in the world. ... I do believe they will find a cure within my nephews lifetime, but we just want to help people in the meantime.

Until theres a cure, we are here to help you understand it, help you get the device you need and information and education you need.

What is TOADS?

Type One Area Diabetics Support, or TOADS, is a new organization formed to fill the gap left when the West Texas Plains branch of the Juvenile Diabetes Research Foundation closed its doors in October. TOADS offers support, education, device drives, tactical kits and scholarships to type 1 individuals and their families. For more information, visit their Facebook page facebook.com/fcftoads or call 806-567-8005.

Read the rest here:
Amarillo group fills gap left by juvenile diabetes foundation's closure ... - Amarillo.com

Posted in Diabetes | Comments Off on Amarillo group fills gap left by juvenile diabetes foundation’s closure … – Amarillo.com

WV Senator Capito reintroduces Preventing Diabetes in Medicare Act – The News Center

Posted: June 8, 2017 at 9:40 am

WASHINGTON, D.C. - U.S. Senators Shelley Moore Capito (R-W.Va.) and Gary Peters (D-Mich.) on Wednesday reintroduced the Preventing Diabetes in Medicare Act, which aims to improve the health of people at risk for diabetes, and save long-term costs for Medicare.

Under current law, Medicare will only cover medical nutrition therapy services for individuals already diagnosed with diabetes or renal disease. This bipartisan legislation would extend Medicare coverage for medical nutrition therapy services for Americans with pre-diabetes and risk factors for developing type-2 diabetes.

With one of the highest rates of adult diabetes in the nation and a considerable pre-diabetes population, West Virginia is no stranger to the costs and challenges associated with this disease, Senator Capito said. The Preventing Diabetes in Medicare Act will help stem the growing rate of diabetes and reduce the one-in-three Medicare dollars being spent on it.

Investing in preventative care for diabetes will save taxpayer dollars by reducing Medicare costs and help at-risk individuals live longer and healthier lives, said Senator Peters. I am proud to reintroduce this commonsense, bipartisan legislation to expand medical nutrition therapy services and help prevent more seniors from developing this chronic and costly condition.

Nearly one in every three Medicare dollars is spent on diabetes, a number that has increased considerably in recent years and will most likely continue to increase without action. The Centers for Disease Control (CDC) estimates approximately 30 million Americans or 9.3 percent of the population have diabetes and approximately 86 million American adults about 30 percent of the population have pre-diabetes.

There is significant evidence to suggest that medical nutrition therapy can prevent the onset of diabetes for at-risk individuals. According to the Agency for Healthcare Research and Quality, $2.5 billion in hospitalization cost related to the treatment of diabetes or complications resulting from diabetes could be saved by providing seniors with appropriate preventive care. Medical nutrition therapy includes an initial nutrition and lifestyle assessment, review of eating habits, one-on-one nutritional counseling and follow-up visits to check on patients progress in managing their diet to prevent or manage their condition.

The Preventing Diabetes in Medicare Act has broad support from major health care groups, including Academy of Nutrition and Dietetics, Spectrum Health, Diabetes Advocacy Alliance, Food is Medicine Coalition, Healthcare Leadership Council, National Association of Nutrition and Aging Services Programs and Michigan Academy of Nutrition and Dietetics.

View post:
WV Senator Capito reintroduces Preventing Diabetes in Medicare Act - The News Center

Posted in Diabetes | Comments Off on WV Senator Capito reintroduces Preventing Diabetes in Medicare Act – The News Center

New Diabetes Drugs May Bring On Ketoacidosis – Healthline

Posted: June 8, 2017 at 9:40 am

Researchers say people with diabetes who took SGLT2 inhibitors were twice as likely to develop the rare condition as those who didnt take the drug.

SGLT2 inhibitors, which are some of the newest diabetes drugs on the market, may increase the risk of a serious condition.

A new study concludes that these medications actually double the likelihood of developing diabetic ketoacidosis.

Because diabetes is becoming more prevalent in the United States, the hunt for new and more effective medication is in full flow.

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent additions to the list of available medicines.

SGLT2 inhibitors reduce blood glucose levels by encouraging the kidneys to increase sugar excretion in urine.

These drugs are often given in combination with other diabetes medications, such as metformin and insulin.

The new class of drugs has become relatively popular, but the latest research finds that they could increase the risk of a serious diabetes-related complication.

Read more: First Indy 500 driver with diabetes talks about life, racing

Diabetic ketoacidosis is relatively uncommon but potentially life-threatening.

It occurs when acids called ketones build up in the body, increasing the acidity of the blood, or when the body does not produce enough insulin.

When insulin is absent, glucose cannot enter cells and provide them with the energy they need.

Therefore, the body falls back on its secondary fuel source: fat. Ketones are byproducts of burning fat.

Symptoms of diabetic ketoacidosis include increased thirst, abdominal pain, nausea and vomiting, and confusion. It can also cause swelling in the brain, and, if left unchecked, can be fatal.

Although diabetic ketoacidosis is more likely to occur in people with type 1 diabetes, it does occasionally appear in individuals with type 2 diabetes.

Read more: Resveratrol may be beneficial to people with diabetes

The new study, carried out by Dr. Michael Fralick and a team from Brigham and Womens Hospital in Boston, set out to examine the interaction, if any, between SGLT2 inhibitors and diabetic ketoacidosis.

The teams findings were published today in the New England Journal of Medicine.

Fralick decided to investigate this relationship after one of his patients with type 2 diabetes showed up at the emergency room with symptoms of diabetic ketoacidosis.

As Fralick explains, My best research projects come from my patients. Their experiences drive the questions I investigate.

In April 2013, SGLT2 inhibitors came onto the market.

Clinical trial data showed that they were relatively safe for use by patients with type 2 diabetes.

However, in 2015, the Food and Drug Administration (FDA) issued a warning on this drug type following reports of increased rates of diabetic ketoacidosis.

Read more: List of diabetes medications

The latest study used data from 40,000 patients and compared the outcomes of individuals taking SGLT2 inhibitors with patients taking a DPP4 inhibitor, which are diabetes drugs that help to maintain higher insulin levels by blocking a specific enzyme.

After 180 days, 26 patients taking the DPP4 inhibitor were diagnosed with diabetic ketoacidosis, compared with 55 individuals taking SGLT2 inhibitors, equating to more than double the risk.

However, it is important to note that diabetic ketoacidosis is still a rare consequence of diabetes, with or without SGLT2 inhibitor use.

The importance of these findings lies more in how doctors might approach treating patients with these types of symptoms.

Although the overall numbers of diabetic ketoacidosis cases are low, Fralick believes that the effect may be even larger than the studys data show.

This is a side effect that's usually seen in patients with type 1 diabetes mellitus - not type 2 - so doctors are not 'on the lookout' for it, Fralick explains. That means that the risk of this side effect might actually be even higher than what we found due to misdiagnosis/under recording.

View original post here:
New Diabetes Drugs May Bring On Ketoacidosis - Healthline

Posted in Diabetes | Comments Off on New Diabetes Drugs May Bring On Ketoacidosis – Healthline

ASU, Mexico partnership takes on biotechnology challenges – Arizona State University

Posted: June 7, 2017 at 6:48 am

June 6, 2017

Never in the history of human existence has the opportunity to genetically modify or protect life been as great and accessible to anyone interested in the topic as it is today.

Cures for human hereditary diseases. Designer babies. Glow-in-the-dark fish. Bioterrorism. Mosquitoes programmed to perish. The opportunities and risks are here now, but lagging are policies, ethical considerations and safety precautions needed to proceed prudently on an international scale.

Arizona State University experts will delve into the issues presented by biotechnology during the annual International Biosafety and Biosecurity Symposium (SIBB) held this year in Morelia, Mexico, and organized by the Asociacin Mexicana de Bioseguridad (AMEXBIO), June 710.

Were enhancing biosafety and biosecurity across international borders, said Irene Mendoza, associate biosafety officer with ASUs Office of Environmental Health and Safety, who will be one of the featured speakers at the symposium. Anything that affects Mexico, like the release of a pathogenic agent, can travel north and affect us.

Although infectious diseases willbe addressed at the symposium, the ASU delegation will lead a technical discussion on gene editing and gene drive technologies, said David Gillum, ASU Environmental Health and Safety associate director and institutional biosafety officer. In simplest terms, its about the ability to modify plants or mammals by manipulating their genome i.e., the chromosomes in each cell of an organism.

These technologies can drive a change in an entire species from just one modification, Gillum said. It can be propagated in all future generations.

David Gillum, ASU Environmental Health and Safety associate director and institutional biosafety officer, said there are many citizen-scientist labs where people are experimenting with gene editing thanks to more accessible technology such as CRISPR Cas9.The risk is that although they may just be trying to do something fun, what they create may have unintended consequences, he said. Photo by Charlie Leight/ASU Now

The gene drive of mosquitoes, for example, can be modified so the specific types that carry malaria and Zika will not reproduce and eventually die off. But once their genome is changed and released into the environment, there is no easy way to predict any unintended consequences.

Thats what is scary about it, Gillum said. Theres no easy undo button.

The leading gene editing method capable of making such changes is called CRISPR Cas9. This technological process takes advantage of the immune systems of bacteria to delete nucleic acids in living cells and replace them with the desired nucleic acid to change the genome.

When youre doing this genome editing, youre looking for very specific nucleic acids to change, Gillum said. Lets consider that you have sickle cell anemia and you have one gene that is wrong, and you just want to target that one gene. But the genome is huge; there are billions of base pairs. So how do you make sure that you target the one that youre looking for and not similar sequences somewhere else in your body?

Unlike past costly and complex genome editing technologies, CRISPR Cas9 is simpler, relatively inexpensive and thus more accessible to people who may not be working in a modern laboratory with established biosafety policies and procedures.

There are a lot of citizen labs all over the place where science enthusiasts getting together in their garages and experimenting, Mendoza said. The risk is that although they may just be trying to do something fun, what they create may have unintended consequences.

Irene Mendoza, associate biosafety officer with ASUs Office of Environmental Health and Safety, will be one of the featured speakers during the annual International Biosafety and Biosecurity Symposium held this week in Morelia, Mexico, and organized by the Asociacin Mexicana de Bioseguridad.

The use of CRISPR Cas9 has increased in Mexico in the past few years, Gillum said. Experts there recognize the challenge, and that drives such events as the SIBB, which includes participation from other Latin American countries.

What we want to achieve in SIBB is to continue the academic efforts of diffusing specific knowledge on biosafety and biosecurity, as well as raise awareness among those involved in manipulating biological agents, said Luis Alberto Ochoa Carrera, AMEXBIO president and founder. The importance of the work of AMEXBIO is based on the need to create a biosafety culture and appropriate communication within institutions to mitigate risks associated with experimenting with biological agents.

ASU contacts AMEXBIO remotely throughout the year, but opportunities exist to engage in person and at a higher level by way of training sessions, site visits, joint research and other symposia to address the wide array of biosafety and biosecurity aspects.

There is a huge opportunity here for ASU and AMEXBIO in Mexico to partner on these projects, Gillum said. Theyre very interested in biodefense. Were looking into philanthropy to help with funding that will allow us to form a more strategic partnership.

With funding, ASU biosafety experts like Gillum and his team can work with AMEXBIO to visit labs in Mexico to observe operations and offer suggestions on improving safety and security.

The interesting aspect of biosafety is that in general its based on best management practices, Gillum said. Except for very highly pathogenic agents and toxins, everything else is done with a best management practices point of view. Theres not always a black-and-white way to do certain things.

Forming strategic links between biosafety and biosecurity experts across the border enables mutual collaboration and training in the region, Ochoa Carrera said.

AMEXBIO recognizes ASUs efforts and transcendence in Mexico and within the international biosafety community, Ochoa Carrera said. The ASU and AMEXBIO alliance enables the dissemination of knowledge in this field, and its also an area of opportunity between Mexico and the United States.

Top photo: DNA sequence, courtesy freeimages.com.

Read more from the original source:
ASU, Mexico partnership takes on biotechnology challenges - Arizona State University

Posted in Biotechnology | Comments Off on ASU, Mexico partnership takes on biotechnology challenges – Arizona State University

The Case for and Against Puma Biotechnology, Inc. (PBYI) – StockNewsJournal

Posted: June 7, 2017 at 6:48 am


Analyst Ratings
The Case for and Against Puma Biotechnology, Inc. (PBYI)
StockNewsJournal
Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $83.65, up from yesterday's close by 2.07%. Given the stock's recent action, it ...
What Should Investors Make Of The Trading Chart Of Puma Biotechnology, Inc. (PBYI)?NY Stock News
Puma Biotechnology Gets a Buy Rating from Cowen & Co.Analyst Ratings
Puma Biotechnology's (PBYI) Buy Rating Reaffirmed at Stifel NicolausSports Perspectives
The Cerbat Gem -StockNewsMagazine -Free Observer -Zacks
all 31 news articles »

Continue reading here:
The Case for and Against Puma Biotechnology, Inc. (PBYI) - StockNewsJournal

Posted in Biotechnology | Comments Off on The Case for and Against Puma Biotechnology, Inc. (PBYI) – StockNewsJournal

Page 1,482«..1020..1,4811,4821,4831,484..1,4901,500..»